Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis.

ABSTRACT:

Background and aim

A large number of studies have tried to combine sorafenib with TACE for patients with unresectable hepatocellular carcinoma (HCC) and the results were controversial. We conducted this systematic review and meta-analysis to evaluate the safety and efficacy of combination therapy of sorafenib and TACE in the management of unresectable HCC.

Methods

MEDLINE, PsycINFO, Scopus, EMBASE, and the Cochrane Library were searched from January 1990 to October 2013 and these databases were searched for appropriate studies combining TACE and sorafenib in treatment of HCC. Two authors independently reviewed the databases and extracted the data and disagreements were resolved by discussion. Effective value and safety were analyzed. Effective value included disease control

SUBMITTER: Liu L 

PROVIDER: S-EPMC3961236 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature